How attacks play outIn this interview, Percheron Therapeutics CEO Dr James Garner discusses the company’s recent pivot to immuno-oncology and the rationale for licensing HMBD-002 as its lead programme. He outlines the potential of HMBD-002 as a novel VISTA-targeting checkpoint inhibitor, its differentiated positioning and the positive preclinical and clinical data reported to date. Dr Garner provides further insight into the ongoing preparatory work for the upcoming Phase II trials in 2026. He also discusses the company’s strategic approach to financing the upcoming studies, and development plans beyond Phase II.

Percheron Therapeutics is a clinical-stage biotech developing next-generation immuno-oncology therapies focused on novel checkpoint pathways, beyond PD-1/L1 and CTLA-4. Its lead asset, HMBD-002, is a first-in-class monoclonal antibody targeting VISTA (an immune checkpoint receptor highly expressed in myeloid cells) and is designed to overcome resistance to existing checkpoint inhibitors.

Bull, Bear & Beyond